Area of Technology:Life Sciences
Title of the Innovation: Development of novel neuroprotective ApoEFragTM for the treatment of Ischemic Stroke
Brief About Innovation
Brief: A dual-domain ApoE-mimetic peptide, one of its own kind peptide with 45 amino acids. It mimics the receptor-binding domain (RBD) and lipid-binding domain (LBD) of human ApoE. ApoEFrag mimics the biological activity of native ApoE.
Dual-domain of peptide (RBD and LBD) provide an advantage that the peptide is able to bind with receptor and lipids, simultaneously, with its respective domains.
Beta Version
Copyright © 2023. NRDC - All Rights Reserved
Designed and Developed by Maxtra Technologies.
